Gunter von Minckwitz

Gunter von Minckwitz

UNVERIFIED PROFILE

Are you Gunter von Minckwitz?   Register this Author

Register author
Gunter von Minckwitz

Gunter von Minckwitz

Publications by authors named "Gunter von Minckwitz"

Are you Gunter von Minckwitz?   Register this Author

100Publications

5664Reads

14Profile Views

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med 2019 02 5;380(7):617-628. Epub 2018 Dec 5.

From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814017
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814017DOI Listing
February 2019

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars.

Oncotarget 2019 Jan 1;10(1):8-9. Epub 2019 Jan 1.

Hans-Christian Kolberg: Marienhospital Bottrop gGmbH, Bottrop, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343751PMC
January 2019

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.

Authors:
Achim Wöckel Jasmin Festl Tanja Stüber Katharina Brust Mathias Krockenberger Peter U Heuschmann Steffi Jírů-Hillmann Ute-Susann Albert Wilfried Budach Markus Follmann Wolfgang Janni Ina Kopp Rolf Kreienberg Thorsten Kühn Thomas Langer Monika Nothacker Anton Scharl Ingrid Schreer Hartmut Link Jutta Engel Tanja Fehm Joachim Weis Anja Welt Anke Steckelberg Petra Feyer Klaus König Andrea Hahne Traudl Baumgartner Hans H Kreipe Wolfram Trudo Knoefel Michael Denkinger Sara Brucker Diana Lüftner Christian Kubisch Christina Gerlach Annette Lebeau Friederike Siedentopf Cordula Petersen Hans Helge Bartsch Rüdiger Schulz-Wendtland Markus Hahn Volker Hanf Markus Müller-Schimpfle Ulla Henscher Renza Roncarati Alexander Katalinic Christoph Heitmann Christoph Honegger Kerstin Paradies Vesna Bjelic-Radisic Friedrich Degenhardt Frederik Wenz Oliver Rick Dieter Hölzel Matthias Zaiss Gudrun Kemper Volker Budach Carsten Denkert Bernd Gerber Hans Tesch Susanne Hirsmüller Hans-Peter Sinn Jürgen Dunst Karsten Münstedt Ulrich Bick Eva Fallenberg Reina Tholen Roswita Hung Freerk Baumann Matthias W Beckmann Jens Blohmer Peter Fasching Michael P Lux Nadia Harbeck Peyman Hadji Hans Hauner Sylvia Heywang-Köbrunner Jens Huober Jutta Hübner Christian Jackisch Sibylle Loibl Hans-Jürgen Lück Gunter von Minckwitz Volker Möbus Volkmar Müller Ute Nöthlings Marcus Schmidt Rita Schmutzler Andreas Schneeweiss Florian Schütz Elmar Stickeler Christoph Thomssen Michael Untch Simone Wesselmann Arno Bücker Andreas Buck Stephanie Stangl

Geburtshilfe Frauenheilkd 2018 Nov 26;78(11):1056-1088. Epub 2018 Nov 26.

Institut für Klinische Epidemiologie und Biometrie (IKE-B), Universität Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0646-4630
Publisher Site
http://dx.doi.org/10.1055/a-0646-4630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261741PMC
November 2018

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.

Geburtshilfe Frauenheilkd 2018 Oct 19;78(10):927-948. Epub 2018 Oct 19.

Universitätsfrauenklinik Würzburg, Universität Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0646-4522
Publisher Site
http://dx.doi.org/10.1055/a-0646-4522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202580PMC
October 2018

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

J Clin Oncol 2018 08 23;36(22):2281-2287. Epub 2018 May 23.

Peter A. Fasching and Matthias Rübner, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen; Sibylle Loibl, Valentina Nekljudova, Karsten E. Weber, and Gunter von Minckwitz, German Breast Group Forschungs, Neu-Isenburg; Christian Schem, University Medical Center Schleswig-Holstein, Kiel; Hans Tesch, Centrum für Hämatologie und Onkologie Bethanien, Frankfurt; Michael Untch, Helios-Klinikum, Berlin-Buch; Jörn Hilfrich, Eilenriede-Klinik, Hannover; Mahdi Rezai, Luisenkrankenhaus; Tanja Fehm, Düsseldorf University Hospital, Heinrich-Heine University of Düsseldorf, Düsseldorf; Bernd Gerber, University of Rostock, Rostock; Serban Dan Costa, Magdeburg University Hospital, Magdeburg; Jens-Uwe Blohmer and Cornelia Liedtke, Charité University Hospital Campus Charité-Mitte, Berlin; Jens Huober, University of Ulm; Brigitte Rack, University Hospital Ulm, Ulm; Volkmar Müller, Hamburg University Hospital, Hamburg, Germany; Chunling Hu, Steven N. Hart, Hermela Shimelis, Raymond Moore, James N. Ingle, and Fergus J. Couch, Mayo Clinic; and Richard M. Weinshilboum and Liewei Wang, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, MN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.2285
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.2285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067803PMC
August 2018

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

J Clin Oncol 2018 05 15;36(13):1308-1316. Epub 2018 Mar 15.

Michael Untch, Helios-Klinikum, Berlin-Buch; Jens-Uwe Blohmer, St Gertrauden Krankenhaus, Berlin; Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Christian Schem, Mammazentrum am Krankenhaus Jerusalem, Hamburg; Mahdi Rezai, Luisenkrankenhaus; Tanja Fehm, Universitäts-Frauenklinik, Düsseldorf; Peter A. Fasching, Universitätsklinikum Erlangen, Erlangen; Hans Tesch, Hämatologisch-Onkologische Gemeinschaftspraxis am Agaplesion Bethanien Krankenhaus; Christine Solbach, Universitäts-Klinikum, Frankfurt; Holm Eggemann, Universitäts-Frauenklinik, Magdeburg; Claus Hanusch, Klinikum zum Roten Kreuz, München; Christian Jackisch, Sana Klinikum Offenbach, Offenbach am Main; Georg Kunz, Klinik für Gynäkologie und Geburtshilfe, Dortmund; Maik Hauschild, Gesundheitszentrum Fricktal, Rheinfelden; and Jens Huober, Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.9175
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.9175DOI Listing
May 2018

Current approach of the axilla in patients with early-stage breast cancer.

Lancet 2017 Aug 14. Epub 2017 Aug 14.

German Breast Group, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)31451-4DOI Listing
August 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

N Engl J Med 2017 Jul 5;377(2):122-131. Epub 2017 Jun 5.

From the German Breast Group, Neu-Isenburg, Germany (G.M.); Frontier Science (Scotland), Kincraig, United Kingdom (M. Procter); the Breast European Adjuvant Study Team (BrEAST) Data Center (E.A., N.R.), the Breast International Group (D.Z., A.A.), and Institut Jules Bordet, Université Libre de Bruxelles (M. Piccart) - all in Brussels; Roche Pharma (M.B., E.C., A.K.) and the Department of Cardiology, Cardio-Oncology, Bern University Hospital (T.S.) - both in Bern, Switzerland; the Department of Pathology, European Institute of Oncology, University of Milan, Milan (G.V.); the National Institute of Oncology, Budapest, Hungary (I.L.); Centre François Baclesse, Caen, France (C.L.); the Sarah Cannon Research Institute and Tennessee Oncology, Nashville (D.A.Y.); Instituto Nacional de Câncer, Rio de Janeiro (J. Bines); Dana-Farber Cancer Institute, Harvard Medical School, Harvard T. H. Chan School of Public Health, and Frontier Science and Technology Research Foundation - all in Boston (R.D.G.); and the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (J. Baselga).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1703643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020PMC
July 2017

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Lancet 2017 Jun 7;389(10087):2430-2442. Epub 2016 Dec 7.

German Breast Group, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)32454-0DOI Listing
June 2017

The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes.

Ann Surg Oncol 2016 10 30;23(10):3093-9. Epub 2016 Jun 30.

German Breast Group c/o: GBG Forschungs GmbH, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5364-3DOI Listing
October 2016

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.

Eur J Cancer 2016 Jan 13;53:65-74. Epub 2015 Dec 13.

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; Universitäts-Frauenklinik Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.022DOI Listing
January 2016

Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.

Breast 2015 Nov 13;24 Suppl 2:S84-7. Epub 2015 Aug 13.

German Breast Group, Neu-Isenburg, Germany; Univ. Women's Hospital Frankfurt, Germany; Senologic Oncology, Düsseldorf, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.020DOI Listing
November 2015

Strategies for developing Ki67 as a useful biomarker in breast cancer.

Breast 2015 Nov 14;24 Suppl 2:S67-72. Epub 2015 Aug 14.

Institute of Pathology, Charité Universitätsmedizin Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.017DOI Listing
November 2015

Neoadjuvant treatment of breast cancer--Clinical and research perspective.

Breast 2015 Nov 19;24 Suppl 2:S73-7. Epub 2015 Sep 19.

German Breast Group, Germany; Senologic Oncology, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.018DOI Listing
November 2015

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.

Future Oncol 2015 ;11(1):61-71

Department of Obstetrics & Gynecology, Breast Cancer Center, Gynecologic Cancer Center, Sana Klinikum Offenbach, Starkenburgring 66, 63069 Offenbach, Germany.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon.14.187
Publisher Site
http://dx.doi.org/10.2217/fon.14.187DOI Listing
September 2015

A step towards a HER2-positive breast cancer super family.

Lancet Oncol 2015 Jul 16;16(7):745-6. Epub 2015 Jun 16.

GBG Forschungs GmbH, 63263 Neu-Isenburg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00037-6DOI Listing
July 2015

Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer.

Int J Cancer 2015 Jun 25;136(11):2730-7. Epub 2014 Nov 25.

Screening and Test Evaluation Program (STEP), Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29323DOI Listing
June 2015

Predictive factors for response to neoadjuvant therapy in breast cancer.

Oncol Res Treat 2014 3;37(10):563-8. Epub 2014 Sep 3.

German Breast Group, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000367643DOI Listing
June 2015

Evolution of adjuvant chemotherapy for breast cancer.

Lancet 2015 May 2;385(9980):1812-4. Epub 2015 Mar 2.

German Breast Group, c/o GBG Forschungs GmbH, 63263 Neu-Isenburg, German.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)62348-5DOI Listing
May 2015

Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today.

J Natl Cancer Inst Monogr 2015 May;2015(51):29-31

German Breast Group, Neu-Isenburg, Germany (GvM, CF); Univ. Women's Hospital, Frankfurt, Germany (GvM); Senologic oncology, Düsseldorf, Germany (GvM); Department of Oncology, University Hospital of Udine, Udine, Italy (CF).

View Article

Download full-text PDF

Source
https://academic.oup.com/jncimono/article-lookup/doi/10.1093
Publisher Site
http://dx.doi.org/10.1093/jncimonographs/lgv007DOI Listing
May 2015

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

J Natl Cancer Inst Monogr 2015 May;2015(51):90-6

Medical Oncology Unit (VA, ABe), University of Brescia, and Breast Unit (RP, LV, ELS) Spedali Civili Hospital, Brescia, Italy; U.O. Multidisciplinare di Patologia Mammaria, S.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Cremona, Italy (DG, AR, MRC, LD, ABo); Departments of Radiation Oncology (TB) and Pathology (FS), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (MC); Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Milan, Italy (GC); Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine (MGD), and Medical Oncology Unit (SDC), Fondazione IRCCS - Istituto Nazionale Tumori, Milan, Italy (MGD); Academic Department of Biochemistry, Biochemical Endocrinology (MD), Department of Surgery, Breast Unit (PB), and The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and Breast Unit (MD, GS), Royal Marsden Hospital, London, UK; Department of Pathology, Melbourne University, Parkville, Australia (SF); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH); Mount Vernon Cancer Centre, London, UK (AM); Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT (CH); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Division of Medical Oncology, Department of Hemato-oncology, IRCCS Policlinico 'San Matteo' Foundation, Pavia, Italy (PP); Dipartimento Medicina di Laboratorio, SC Anatomia ed Istocitopatologia Diagnostica e di Screening, A.O.U. Città della Salute e della Scienza di Torino, Università di Torino, Turin, Italy (AS); N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia (VS); German Breast Group & University of Frankfurt, Neu-Isenburg, Germany (GvM); The Russell H. Morgan Department of Radiology

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009414PMC
May 2015

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

J Clin Oncol 2015 Mar 22;33(9):983-91. Epub 2014 Dec 22.

Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1967DOI Listing
March 2015

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.

J Clin Oncol 2015 Mar 17;33(9):1045-52. Epub 2015 Feb 17.

Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense; Noelia Martinez, University Hospital Ramón y Cajal; José Ángel Garcia-Saenz, University Hospital Clínico San Carlos; Eva Carrasco, Grupo Español de Investigación en Cáncer de Mama, Madrid; Serafín Morales, Hospital Arnau de Vilanova de Lérida, Lérida; Angel Guerrero, Valencian Institute of Oncology, Valencia; Antonio Anton, University Hospital Miguel Servet, Zaragoza; Montserrat Muñoz, University Hospital Clinic i Provincial; Mireia Margeli, Hospital Universitario Germans Trias i Pujol, Barcelona; Miguel Gil, Catalan Institute of Oncology, Hospitalet; Manuel Ramos, Centro Oncológico de Galicia, La Coruña; Juan R. De la Haba-Rodriguez, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) -Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, German Breast Group, Neu-Isenburg; Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, Sana Klinikum Offenbach, Offenbach; Bahriye Aktas, University Women's Hospital Essen, Essen; Winfried Schoenegg, Medical Practice Berlin, Berlin; Cornelia Liedtke, University Women's Hospital Münster, Münster; Cornelia Liedtke, University Hospital Lübeck, Lübeck; and Grischa Wachsmann, Klinikum Böblingen, Böblingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.2388DOI Listing
March 2015

Pathological complete response in breast cancer--authors' reply.

Lancet 2015 Jan;385(9963):114-5

German Breast Group, Neu-Isenburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)60018-6DOI Listing
January 2015

Current and future role of neoadjuvant therapy for breast cancer.

Breast 2014 Oct 14;23(5):526-37. Epub 2014 Jul 14.

German Breast Group c/o GBG Forschungs GmbH, Neu Isenburg, Germany; University Women's Hospital, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.06.004DOI Listing
October 2014

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

J Clin Oncol 2014 Oct 8;32(29):3212-20. Epub 2014 Sep 8.

Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7876DOI Listing
October 2014

Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.

J Clin Oncol 2014 Oct 15;32(30):3458-9. Epub 2014 Sep 15.

German Breast Group, Neu-Isenburg; and Sana-Klinikum Offenbach, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0499DOI Listing
October 2014

RANK expression as a prognostic and predictive marker in breast cancer.

Breast Cancer Res Treat 2014 Jun 16;145(2):307-15. Epub 2014 Apr 16.

Institute of Pathology, Campus Mitte, Charité University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2955-1DOI Listing
June 2014

Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Reply to K.-D. Yu et al.

J Clin Oncol 2014 Apr 17;32(12):1283-4. Epub 2014 Mar 17.

German Breast Group, Neu-Isenburg; University Hospital Frankfurt, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.4437
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.4437DOI Listing
April 2014

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy.

Oncoimmunology 2014 14;3:e27926. Epub 2014 Feb 14.

Institute of Pathology; Charité-Universitätsmedizin Berlin; Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.27926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203634PMC
February 2014

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.

Breast Care (Basel) 2013 Mar;8(1):60-6

German Breast Group, Neu-Isenburg, Universitätsklinikum München, Klinikum Offenbach, Germany ; Brustzentrum, Klinikum Offenbach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000346834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971817PMC
March 2013